Graham K. Cooper - 06 Jul 2021 Form 4 Insider Report for Beam Therapeutics Inc. (BEAM)

Role
Director
Signature
By: /s/ Christine Bellon, Attorney-in-fact
Issuer symbol
BEAM
Transactions as of
06 Jul 2021
Net transactions value
-$270,825
Form type
4
Filing time
08 Jul 2021, 18:00:40 UTC
Previous filing
30 Jun 2021
Next filing
31 Jan 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction BEAM Common Stock Options Exercise $44,438 +2,614 $17.00 2,614 06 Jul 2021 Direct F1
transaction BEAM Common Stock Sale $70,843 -614 -23% $115.38 2,000 06 Jul 2021 Direct F2, F3
transaction BEAM Common Stock Sale $23,282 -200 -10% $116.41 1,800 06 Jul 2021 Direct F2, F4
transaction BEAM Common Stock Sale $23,670 -200 -11% $118.35 1,600 06 Jul 2021 Direct F2, F5
transaction BEAM Common Stock Sale $11,968 -100 -6.2% $119.68 1,500 06 Jul 2021 Direct F2, F6
transaction BEAM Common Stock Sale $24,078 -200 -13% $120.39 1,300 06 Jul 2021 Direct F2, F7
transaction BEAM Common Stock Sale $48,636 -400 -31% $121.59 900 06 Jul 2021 Direct F2, F8
transaction BEAM Common Stock Sale $12,285 -100 -11% $122.85 800 06 Jul 2021 Direct
transaction BEAM Common Stock Sale $24,752 -200 -25% $123.76 600 06 Jul 2021 Direct F2, F9
transaction BEAM Common Stock Sale $37,293 -300 -50% $124.31 300 06 Jul 2021 Direct F2, F10
transaction BEAM Common Stock Sale $12,651 -100 -33% $126.51 200 06 Jul 2021 Direct
transaction BEAM Common Stock Sale $12,867 -100 -50% $128.67 100 06 Jul 2021 Direct
transaction BEAM Common Stock Sale $12,938 -100 -100% $129.38 0 06 Jul 2021 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction BEAM Stock Option (Right to Buy) Options Exercise $0 -2,614 -14% $0.000000 16,561 06 Jul 2021 Common Stock 2,614 $17.00 Direct F1, F11
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The stock option exercise reported in this Form 4 was effected pursuant to a 10b5-1 trading plan.
F2 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. The sale price reported is a weighted average price. The Reporting Person undertakes to provide to Beam Therapeutics Inc. ("BEAM"), any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $115.04 to $115.88, inclusive.
F4 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $116.13 to $116.69, inclusive.
F5 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $118.00 to $118.71, inclusive.
F6 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $119.67 to $119.68, inclusive.
F7 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $120.37 to $120.40, inclusive.
F8 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $121.19 to $121.96, inclusive.
F9 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $123.64 to $123.88, inclusive.
F10 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $124.28 to $124.33, inclusive.
F11 The option vests as to one third on the first anniversary of the of the vesting commencement date, February 5, 2020, and at a rate of 4.17% each month thereafter until the option is fully vested.